Reducing Heart Scarring in Heart Failure with Preserved Pumping
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a medication (sacubitril/valsartan) to reduce scarring in the heart muscle for people with a type of heart failure where the heart pumps well but is stiff. The goal is to see if it can improve heart function and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older.
- You have been diagnosed with heart failure with a preserved pumping function (ejection fraction of 45% or more).
- You are able to have an MRI (no metal implants, pacemaker, or severe claustrophobia).
- Your blood pressure is not too low (systolic over 100 or 110 depending on meds) and you don't have dizzy spells from low BP.
- Your kidney function is adequate (eGFR at least 30) and potassium levels are not too high.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination medication (sacubitril/valsartan) can improve the heart's ability to relax and fill properly in people with heart failure and a very weak heart pump (ejection fraction less than 35%). It's for patients who are already on standard heart failure medicines.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
This trial tests a drug called sacubitril/valsartan to see if it helps people who have both a prosthetic heart valve and heart failure with a weak heart pump. The goal is to improve heart function and symptoms.
This trial studies whether sacubitril-valsartan works better than enalapril to improve heart healing after a specific type of heart attack. It aims to see if the heart’s shape and pumping recover more effectively.
This test looks at sacubitril/valsartan — a heart failure pill — in people who have a type of amyloidosis that affects the heart (called ATTR amyloidosis) and who also have a heart that pumps weakly (ejection fraction 40% or less). The goal is to see if it helps heart function and daily life.
This study tests an approach aimed at reducing heart scarring (fibrosis) after heart failure. It enrolls people with moderate to severe heart failure who have signs of active heart strain and can complete study tests.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.